Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x100px
Organisation › Details

Alligator Bioscience (Group)

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. *

 

Period Start 2000-12-01 established
  Predecessor University of Lund (Lund University)
Products Industry FIND® technology (Fragment INduced Diversity)
  Industry 2 mitazalimab (ADC-1013)
Persons Person Norlén, Per (Alligator Bioscience –202103 CEO)
  Person 2 Benson, Peter (Sunstone Capital 200705– Managing Partner Life Science Ventures)
     
Region Region Lund
  Country Sweden
  City 22381 Lund
  Tel +46-46-286-4280
    Address record changed: 2020-12-02
     
Basic data Employees C: 51 to 100 (2019-12-31)
  Currency SEK
  Annual sales 4,352,000 (sales, net, consolidated (2020) 2020-12-31)
  Profit -143,296,000 (2020-12-31)
  Cash 103,342,000 (2020-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-02-12

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Alligator Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px




» top